All Stories

  1. Shaping the neurological health agenda in the Americas: from mortality to chronic disability
  2. Neurorights: safeguarding mental integrity in the face of neurotechnology
  3. Exploring the association between interoceptive awareness and neuropsychiatric symptoms in people living with Parkinson's disease
  4. Huntington's disease in the era of somatic instability, biomarkers, and targeted therapies: A narrative review
  5. Essential genetic testing in movement disorders – results from a Delphi study
  6. Contribuciones de enfermería en el abordaje holístico de la enfermedad de Parkinson
  7. The spectrum of psychosis in people with neurological disease
  8. Association of a five-metabolite and early-symptom profile with Parkinson’s disease and its clinical progression
  9. TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations
  10. An international 20 country patient and physician survey of the usability and acceptability of Stepped Care pathway in Parkinson’s disease
  11. Incidence of Sporadic Creutzfeldt-Jakob Disease in the Emergency Department
  12. Unraveling the Link between Sleep Disturbances and Parkinson’s Disease: A Narrative Review
  13. Developing personalized treatment strategies for Parkinson’s disease based on disease subtypes
  14. EPIDEMIOLOGY OF LEVODOPA-INDUCED DYSKINESIA: PREVALENCE AND ASSOCIATED CLINICAL FACTORS IN LATIN AMERICA
  15. Genotype-phenotype association study conducted on LARGE-PD reveals novel loci associated with Parkinson’s Disease
  16. Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study
  17. Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores
  18. Condiciones de igualdad entre médicas y médicos en 2021 en el Instituto Nacional de Neurología y Neurocirugía
  19. Influencia del sexo y del estado funcional en el bienestar emocional en la enfermedad de Parkinson: conocimientos de un estudio transversal
  20. Sex differences in the diagnosis latency of Parkinson's disease in Latin America
  21. The LRRK2 p.L1795F variant causes Parkinson’s disease in the European population
  22. Establishing a MoCA cut-off point for cognitive impairment detection in Mexican people living with Parkinson's disease: A comprehensive assessment (level II) approach
  23. Revisión exploratoria sobre los tratamientos experimentales para la enfermedad de Parkinson: terapias de precisión y de amplio espectro
  24. Factores de riesgo para el desarrollo de trastornos del control de impulsos en sujetos mexicanos con enfermedad de Parkinson
  25. Association between alterations in sleep spindles and cognitive decline in persons with Parkinson’s disease
  26. Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study
  27. Weak association between total alpha‐synuclein reflex tear levels and non‐motor symptoms burden in Parkinson's disease
  28. Movement disorders in opioid users observed in the social networks: a systematic review
  29. Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?
  30. A Characterization of Central Auditory Processing in Parkinson’s Disease
  31. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
  32. Building national patient registries in Mexico: insights from the MexOMICS Consortium
  33. Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome
  34. The Importance of Standardized Assessment
  35. Levodopa Versus Levodopa Sparing in Early Parkinson‘s Disease: Can we Meet Halfway?
  36. Electrocardiographic approach strategies in patients with Parkinson disease treated with deep brain stimulation
  37. Establishment of induced pluripotent stem cell lines derived from Parkinson’s disease Mexican patients: A sporadic (UNAMi002-A) and a familial (UNAMi003-A) case carrying a mutation in PINK1
  38. Parkinson's disease-associated pain in a Mexican Institute
  39. Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose‐Driven Approach
  40. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus
  41. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
  42. Impulse control disorders and its association to medication use and other associated factors in patients with Parkinson's disease
  43. Pro-inflammatory cytokines levels in tears and dry eye disease in Parkinson’s disease
  44. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study
  45. Building National Patient Registries in Mexico: Insights from the MexOMICS Consortium.
  46. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)
  47. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
  48. Clinical and genetic insights of Parkinson’s Disease in a Mexican cohort: highlighting Latino’s diversity
  49. Neuropsychiatric and young-onset as clinical determinants for a delayed HuntingtonÓ?s disease diagnosis
  50. Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset
  51. Determinants and impact of alexithymia on quality of life in Parkinson's disease
  52. Is there any correlation between alpha-synuclein levels in tears and retinal layer thickness in Parkinson's disease?
  53. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
  54. Association between cardiometabolic comorbidities and Parkinson’s disease in a Mexican population
  55. Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic
  56. Documento de postura: la afectación de personal médico y de la salud en la pandemia de SARS-CoV-2
  57. Expanded and Independent Spanish Validation of the MDS‐Non Motor Rating Scale
  58. Experience with Creutzfeldt-Jakob disease in a single referral center in Mexico. Case series
  59. Attentional impairment in Parkinson’s disease is modulated by side of onset: Neurophysiological evidence
  60. Association between dopaminergic-induced complications and life satisfaction in ParkinsonÓ?s disease
  61. Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinson’s disease
  62. COVID-19 and Integrated Multidisciplinary Care Model in Parkinson’s Disease: Literature Review & Future Perspectives
  63. Pitfalls and caveats in the diagnostic pathway of people with ParkinsonÓ?s disease
  64. Experiencia con la enfermedad de Creutzfeldt-Jakob de un único centro de referencia en México. Análisis de una serie de casos
  65. Fellowship training: a collateral damage of Covid-19 pandemic
  66. Living with chronic illness scale in Parkinson's disease: Longitudinal metric properties and meaningful change
  67. Naturalistic Study of Depression Associated with Parkinson’s Disease in a National Public Neurological Referral Center in Mexico
  68. Satisfaction With Telemedicine Consultation as Follow-Up Visit in Patients with Parkinsonism and Essential Tremor in during the Covid-19 Pandemic
  69. Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
  70. Spotlight on non-motor symptoms and Covid-19
  71. The neuropsychiatry of Parkinson's disease: advances and challenges
  72. Editorial: Managing Parkinson's Disease With a Multidisciplinary Perspective
  73. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson’s disease
  74. Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana
  75. Self-reported olfactory dysfunction in Mexican healthcare workers during the first six months of the COVID-19 pandemic: A nationwide online survey study
  76. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
  77. Pro- and anti-inflammatory response in neurological disorders associated to anti-glutamate decarboxylase antibodies
  78. Editorial: Measurement Tools for Clinical Assessment, Characterization and Neurorehabilitation of Parkinson's Disease
  79. Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life
  80. Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
  81. Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations
  82. Worldwide barriers to genetic testing for movement disorders
  83. Frontal functional connectivity and disease duration interactively predict cognitive decline in Parkinson's disease
  84. Incidencia y distribución geográfica de la enfermedad de Parkinson en México
  85. Malnutrition and Associated Motor and Non-motor Factors in People with Parkinson's Disease
  86. Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease
  87. Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations
  88. First report of pathogenic SGCE variants in Mexican patients with myoclonus dystonia: A five-year follow-up study
  89. Manifestaciones neurológicas en la enfermedad del coronavirus 2019
  90. Neuropsychiatric profile of patients with craniocervical dystonia: A case-control study
  91. Editorial: Patient Empowerment and Person-Centered Care in Movement Disorders
  92. Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson’s Disease
  93. Teaching neurology to “Millennials:” Basic concepts and recommendations
  94. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease
  95. Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson’s disease
  96. Review of Hereditary and Acquired Rare Choreas
  97. Factores asociados con deterioro cognitivo en una cohorte mexicana multicéntrica de Parkinson: estudio transversal comparativo
  98. Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al.
  99. Falls in persons with Parkinson's disease: Do non-motor symptoms matter as much as motor symptoms?
  100. Gait in Parkinson’s Disease
  101. Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease
  102. Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly
  103. Incidence rates of Parkinson’s disease in Mexico: Analysis of 2014-2017 statistics
  104. Análisis de subtipos motores en la enfermedad de Parkinson: Registro Mexicano de Enfermedad de Parkinson (ReMePARK)
  105. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations
  106. Influencing factors when living with Parkinson’s disease: A cross‐sectional study
  107. Air Pollution, Multiple Sclerosis and its Relevance to Mexico City
  108. Terapias de infusión en la enfermedad de Parkinson avanzada
  109. The Parkinson's Disease Sleep Scale–2 (PDSS‐2): Validation of the Spanish Version and Its Relationship With a Roommate‐Based Version
  110. Brief historical review of Parkinson’s disease at 200 years of its description
  111. Low diagnostic accuracy of fragile X tremor/ataxia syndrome diagnostic criteria in late onset ataxia
  112. Diseño y evaluación curricular de un curso de posgrado de alta especialidad en medicina
  113. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
  114. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción
  115. Huntington's disease-like disorders in Latin America and the Caribbean
  116. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease
  117. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
  118. Etiología, fenomenología, clasificación y tratamiento de la distonía
  119. Indirect Costs of Parkinson Disease Health Care in the National Institute of Neurology and Neurosurgery in the Mexico City
  120. Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism
  121. Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations
  122. Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease
  123. Two-hundred Years Later: Is Parkinson�s Disease a Single Defined Entity?
  124. Premotor symptoms and the risk of Parkinson’s disease: A case-control study in Mexican population
  125. Treatable inherited rare movement disorders
  126. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
  127. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative a...
  128. Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population
  129. Spotlight on olfactory dysfunction in Parkinson's disease
  130. Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms
  131. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
  132. Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale
  133. Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings
  134. Living with chronic illness scale: international validation of a new self-report measure in Parkinson’s disease
  135. Analysis of four scales for global severity evaluation in Parkinson’s disease
  136. Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population
  137. Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
  138. Frequency and clinical correlates of postural and striatal deformities in Parkinson’s disease
  139. Parkinson disease and progressive supranuclear palsy: protein expression in skin
  140. A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America
  141. Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson's disease
  142. Theory of the mind in subjects with Parkinson's disease: A case-control study
  143. Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson’s Disease
  144. Frecuencia de polimorfismos de nucleótido único y haplotipos de alfa-sinucleína asociados con la enfermedad de Parkinson esporádica en población mexicana
  145. Convergent validation of EQ-5D-5L in patients with Parkinson's disease
  146. Delusional Parasitosis as a Treatment Complication of Parkinson Disease
  147. The P3a wave: A reliable neurophysiological measure of Parkinson’s disease duration and severity
  148. No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease
  149. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson’s Disease
  150. Electroconvulsive therapy in Parkinson´s disease
  151. Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador
  152. Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers
  153. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study
  154. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
  155. Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease
  156. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
  157. A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
  158. Cardiovascular variability in Mexican patients with Parkinson's disease
  159. Impulse control and related disorders in Mexican Parkinson's disease patients
  160. Comparing the accuracy of different smell identification tests in Parkinson’s disease: Relevance of cultural aspects
  161. Simultaneous Presentation of Ocular Flutter in Two Sisters
  162. Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration
  163. Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson’s disease with w Low Educational Background
  164. Vas Eq-5d Utility Index In Parkinson’s Disease
  165. Direct Medical Costs Related To Parkinson’s Disease
  166. A Relationship Between Eq-5d Health State Classifications And Eq Vas Scores In Parkinson’s Disease
  167. A reappraisal of the ten steps test for identifying atypical parkinsonism
  168. Initial circulatory response to active standing in Parkinson's disease without typical orthostatic hypotension
  169. Genetic mutations in early-onset Parkinson's disease Mexican patients: Molecular testing implications
  170. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients
  171. Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease
  172. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA
  173. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  174. Cervical Dystonia
  175. Apathy and associated factors in Mexican patients with Parkinson’s disease
  176. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease
  177. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale
  178. Respuesta ortostática de la tensión arterial de pacientes con enfermedad de Parkinson inicial
  179. Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson’s Disease
  180. Prevalence and determinants of depression in Mexican patients with Parkinson's disease
  181. Overweight is more prevalent in patients with Parkinson's disease
  182. Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies
  183. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
  184. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease
  185. Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
  186. High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease
  187. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  188. A prospective series of patients with hyperglycaemia-associated movement disorders
  189. Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
  190. Relación entre el tipo y lado de inicio de la sintomatología motora con la frecuencia de síntomas no motores en la enfermedad de Parkinson
  191. Involuntary attention impairment in early Parkinson's disease: An event-related potential study
  192. Sympathetic Cooling in an Optically Trapped Mixture of Alkali and Spin-Singlet Atoms
  193. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease
  194. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
  195. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease
  196. Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study
  197. Association of a history of varicella virus infection with multiple sclerosis
  198. SEQUENTIAL STAR FORMATION IN A COMETARY GLOBULE (BRC37) OF IC1396
  199. Uso clínico de autoanticuerpos en neurología
  200. Quality of life in patients with Parkinson's disease